Investigational drug · Phase 3
NPI-001
Also called: N-Acetylcysteine Amide
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Retinitis Pigmentosa (RP), Usher Syndrome, Alzheimer´s Disease.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
3 still active
All registered trials
6
Any phase or sponsor naming "NPI-001"
First trial start
2020
Sep 3, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NPI-001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Retinitis Pigmentosa (RP)
- Usher Syndrome
- Alzheimer´s Disease
- Cystinosis
- Usher Syndromes
Approved drugs for the same conditions: Alzheimer's disease · Neurology · Rare and genetic disease · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "NPI-001" as an intervention, largest first.
- A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher SyndromePivotal-lookingRecruiting
Nacuity Pharmaceuticals, Inc.Industry
NCT07710196 · 80 participants (planned) · Start Oct 23, 2026 · Primary completion Apr 2029
Drug: Placebo; NPI-001 · For: Retinitis Pigmentosa (RP); Usher Syndrome
Sites: Dallas, Texas
- 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher SyndromePivotal-lookingNot yet recruiting
Nacuity Pharmaceuticals, Inc.Industry
NCT07290530 · 80 participants (planned) · Start Dec 2026 · Primary completion Jul 2029
Drug: N-acetylcysteine amide · For: Retinitis Pigmentosa (RP); Usher Syndrome
Nacuity Pharmaceuticals, Inc.Industry
NCT04355689 · 49 participants · Start Sep 3, 2020 · Primary completion Jun 20, 2025
Drug: NPI-001 · For: Usher Syndromes
Sites: Brisbane, Australia; Melbourne, Australia; Perth, Australia · 4 sites in all
- Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI or Alzheimer's Disease (AD)Active, not recruiting
Arctic TherapeuticsIndustry
NCT07741526 · 33 participants · Start Oct 14, 2025 · Primary completion Apr 30, 2027
Drug: NPI-001; Placebo · For: Alzheimer´s Disease
Sites: Gandrup, Denmark; Herlev, Denmark; Vejle, Denmark · 4 sites in all
- Safety, Tolerability and Efficacy of NPI-001 in Patients With Hereditary Cystatin C Amyloid Angiopathy (HCCAA)Active, not recruiting
Arctic TherapeuticsIndustry
NCT07716865 · 15 participants · Start Apr 3, 2024 · Primary completion Dec 29, 2026
Drug: NACA · For: Hereditary Cystatin C Amyloid Angiopathy (HCCAA); Hemorrhage Brain; Hemorrhage Cerebral
Sites: Reykjavik, Iceland
Nacuity Pharmaceuticals, Inc.Industry
NCT05994534 · 8 participants · Start Oct 29, 2023 · Primary completion May 26, 2026
Drug: Cysteamine Bitartrate; N-Acetylcysteine Amide · For: Cystinosis
Sites: Westmead, Australia
Newest research
PubMed records naming it or its code names, newest first.
- SCOPE: A Spatial Co-registration and Omics Pipeline for Comparative Mass Spectrometry Imaging Data Analysis.
Shi D, MacFarlane E, Boughton BA, et al. · Comput Struct Biotechnol J 2026
- Antioxidant modulation of stress behavior depends on stress coping style: A role for N-acetylcysteine amide.
Wong RY, Schmidt BK, Gibson CR, et al. · Pharmacol Biochem Behav 2026
- Elevated neuronal TAF15 expression induces oxidative stress and anxiety-related behavioral deficits.
Yi T, Guan H, Li J, et al. · Cell Rep 2026
- Antioxidant modulation of stress behavior depends on stress coping style: a role for N-acetylcysteine amide.
Wong RY, Schmidt BK, Gibson CR, et al. · bioRxiv 2026
- Correction: Alkandari et al. N-Acetylcysteine Amide Against Aβ-Induced Alzheimer's-like Pathology in Rats. Int. J. Mol. Sci. 2023, 24, 12733.
Alkandari AF, Madhyastha S, Rao MS · Int J Mol Sci 2026
- Redefining the role of the thiol-based agent N-acetylcysteine in human health and disease and elucidating potential advantages of its amide derivative.
Qu HQ, Kao C, Hakonarson H · RSC Med Chem 2026
Also in development for Retinitis Pigmentosa (RP)
- RTx-015Phase 31 trial
Ray Therapeutics, Inc. · Retinitis Pigmentosa (RP), Inherited Retinal Diseases
- Intravitreal of UltevursenPhase 22 trials
Laboratoires Thea · Retinitis Pigmentosa (RP), Usher Syndrome Type 2, Deaf Blind
- OpCT-001Phase 21 trial
BlueRock Therapeutics · Primary Photoreceptor Disease, Retinitis Pigmentosa (RP), Usher Syndrome
- SPVN20Phase 21 trial
SparingVision · Retinitis Pigmentosa (RP), Rod Cone Dystrophy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.